article · The Lancet

Switch to single-tablet bictegravir–lenacapavir from a complex HIV regimen (ARTISTRY-1): a randomised, open-label, phase 3 clinical trial

Chloe Orkin
Anita Scribner
William E Sanchez
JIHAD SLIM
P Shalit
Simiso Sokhela
Malcolm Hedgcock
Jorge L. Santana Bagur
Clinton Haley
Jörg Claus
Alexandra Stang
Cynthia Brinson
Emma Rubenstein
James L. Sims
Sadi M Dar
David James Prelutsky
Edwin DeJesus
P. N. Ruane
Moreno Guillén S
Jairo M. Montezuma-Rusca
Daniel S Berger
Ricky K Hsu
Ronald Poblete
Takuma Shirasaka
Savannah Cranford
Jeffrey H. Burack
Andrea Antinori
M-S Han
Keith Aizen
Linda Gorgos
Edwin DeJesus
Celia Jonsson-Oldenbüttel
Jade Ghosn
José Ignacio Bernardino de la Serna
Onyema Ogbuagu
Jason Brunetta
Frank Post
Marcus Tellez
Peter Sklar
Marcelo H Losso
Lizette Santiago
Mark O'Reilly
Yashna Singh
Michael Sension
Hung-Chin Tsai
Carlos Adon Moreta
Thomas Lutz
Yoshiyuki Yokomaku
Susan Little
Blair Thedinger

2026University of the Witwatersrand

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

View on publisher site Record on OpenAlex

DOI: 10.1016/s0140-6736(26)00307-7

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.

New to MARATTO™? Create a free account.

Switch to single-tablet bictegravir–lenacapavir from a complex HIV regimen (ARTISTRY-1): a randomised, open-label, phase 3 clinical trial

In plain language

Research topics

Read the original research

Discuss this research